Meta-analysis examining phosphodiesterase-5 inhibitors in heart failure with preserved ejection fraction

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Heart failure with preserved ejection fraction (HFpEF) is associated with reduced cyclic guanosine 3',5'-monophosphate (cGMP) levels.
• Phosphodiesterase-5 (PDE5) inhibitors enhance the cGMP pathway, suggesting potential cardioprotective effects in HFpEF.

Purpose of the Study:

• To systematically evaluate the efficacy of PDE5 inhibitors in patients with HFpEF.
• To assess the impact of PDE5 inhibitors on exercise capacity and cardiac function in HFpEF.

Main Methods:

• Systematic search of randomized trials from PubMed, Embase, and Google Scholar.
• Data analysis using RevMan (version 5.4).
• Inclusion of 221 subjects in the PDE5 inhibitor group and 202 in the control group.

Main Results:

• No significant differences observed between groups in peak oxygen consumption or 6-minute walking distance.
• No significant differences in echocardiographic parameters (mitral annular E/e' ratio, left ventricular ejection fraction) or hemodynamic measures (pulmonary artery pressures, pulmonary vascular resistance).

Conclusions:

• PDE5 inhibitors did not demonstrate significant benefits for exercise capacity or cardiac function in HFpEF patients.
• The potential cardioprotective role of PDE5 inhibitors in HFpEF requires further investigation.